Based on these findings, increasing moesin expression should be anti-oncogenic in pancreatic cancer, and would align with elevated moesin protein levels observed particularly with PAD2 inhibitor treatment in Panc-1 cells in the current study. This evidence concerns the gene MSN and familial pancreatic carcinoma.